Clinical phase I studies established tolerability and safety of TRAIL without dose-limiting toxicity (DLT), either as single-agent or in combination with conventional chemotherapeutic drugs for advanced non-small-cell lung cancer (NSCLC), non-Hodgkin lymphoma, colorectal cancer, advanced cancers, and B-cell lymphoma [91,92,93,94,95,96,97]. This evidence concerns the gene TNFSF10 and non-small cell lung carcinoma.